Mutations in breast cancer susceptibility gene 2 (BRCA2) can lead to chromosomal instability and result in breast cancer, which is strongly associated with p53 mutations. Here, based on the crystal structure of BRC4 and p53, the spatial structure of BRC2 and p53 (171-192) was simulated, providing structural basis for the site-specific mutation of BRC2. The BRC analogous peptides and p53 were synthesized, and the interaction between the mutant peptide and p53 (171-192) was studied using circular diachronic spectroscopy and fluorescence spectroscopy. The results show that the mutations of amino acid residues constituting the BRC2 a-helix significantly affect the structure and interaction of BRC analogs and p53 , which provides support for understanding the structure of the BRC repeat motifs and its interaction pattern with p53.
The incidence of breast cancer has been increasing in recent years, with increasing occurrence of the disease at a young age being observed. According to global statistics, more than 1.38 million people are diagnosed with breast cancer each year [1] . The incidence of breast cancer involves the interaction of a variety of genes and their products. At present, increasing attention is focused on the interaction between breast cancer susceptibility gene 2 (BRCA2) and tumor suppressor genes p53 and RAD51 [2] .
The human BRCA2 gene is located on chromosome 13q12-13 and encodes a protein containing 3418 amino acid residues [3] . The binding of the BRCA2 protein to the recombinase RAD51 is a critical step in homologous chromosomal recombination and plays a crucial role in the DNA repair pathway. BRCA2 mutation inactivates the protein function of repairing DNA damage, leading to chromosomal instability and resulting in the occurrence of breast cancer and the appearance of ovarian and pancreatic cancers [4] . The human BRCA2 protein contains eight highly conservative BRC repeat motifs in its 1003-2085 sequence. The BRC motif is conserved among different species, indicating that BRC is a key functional domain of the BRCA2 protein [5] .
Protein-protein interaction are ubiquitous in nature and play key roles in many cellular processes including apoptosis, gene expression, and DNA repair. In BRCAassociated cancers, BRCA2 mutation is strongly associated with p53 mutation. Approximately 70% of patients with BRCA2 mutation present p53 mutation [6] . The p53 protein is a main regulatory protein that participates in apoptosis, DNA repair, and cell cycle regulation. In addition, p53 can interact with numerous key proteins involved in homologous recombination, such as RAD51 and RecA [7] . The human p53 gene is located on chromosome 17, encoding a protein containing 393 amino acid residues. The 100-200 sequence in p53 protein is its conservative peptide. Mutation in this region causes the malignant transformation of the tumor to exceed 80%. The p53 DNA-binding domain is in this peptide [8] .
Although the BRCA2 repeat motif BRC4 can directly interact with RAD51, the DNA-binding domain of p53 can bind to the region of BRCA2 containing BRC repeat motifs, and p53 and BRCA2 cooperate to regulate RAD51 and inhibit tumor production [9] [10] [11] . However, the site and mechanism of direct action between p53 and BRCA2 remain unclear. In this work we targeted the protein-protein interaction between p53 and the tumor suppressor protein, BRCA2. On the basis of the crystal structure of BRC4 and p53, this paper simulates the spatial structure of BRC2 and p53 , that is, 171-192 peptide segment in p53. This work also mutates certain sites in the BRC2 sequence based on the simulation result, and preliminarily studies the interaction between the mutant peptide and p53 (171-192). We provide ideas and support for understanding the structure of BRC repeat motifs, the interaction between BRCA2 and p53, and the design of polypeptide drugs.
Materials and methods

Materials
Fmoc-AA-Wang Resin, Fmoc-AA-OH, 1-hydroxybenzotriazole hydrate (HOBT), 2-(1H-benzotriazole-1-yl)-1,1,3, 3-tetramethyluronium hexafluorophosphate (HBTU), and N,N-diisopropylethylamine (DIEA), trifluoroacetic acid (TFA) were purchased from GL Biochem Ltd. (Shanghai, China). Piperidine, dimethylformamide (DMF), acetonitrile, and methanol were purchased from Tianji Siyou Fine Chemicals Company (Tianjin, China). Ethanethiol (EDT), and thioanisole were purchased from Aladdin Industrial Corporation (Shanghai, China). Ninhydrin, phenol, and ether were provided by Shanghai Crystal Pure Reagent Co. Ltd (Shanghai, China). All reagents used were of analytical grade.
Structure stimulation of BRC2-p53 (171-192) and design of BRC2 mutations Structure of p53 (171-192) was obtained from PDB bank (PDB number: 2PCX). The structure of BRC2 was formed by homologous modeling, using the 'Create Homology Models' tool in the computing platform 'Discovery Studio 2017 R2(DS)' based on the structure of BRC4 (PDB bank: 1N0W) [12] . The docking program between p53 (171-192) and BRC2 is ZDOCK module and Refine Protein Docking (RDOCK) module. ZDOCK was run with at 6 o rotational sampling, other parameters are default. The top 10 structures presenting the highest ZDOCK score were chosen and further optimized using RDOCK module [13, 14] . The mutations of amino acid residues of BRC2 were designed in accordance with the simulation structure of the BRC2-p53 (171-192) complex. And the complex of mutant and p53 (171-192) was used to perform an alanine scanning mutagenesis study, evaluating the binding free energy for complex conformation .
Synthesis of polypeptides
The peptides were synthesized using Fmoc solid-phase method [15] . The syntheses of BRC peptides are different on the amino acids used for coupling. Purified peptides were afforded via RP-HPLC. Purified products were freeze-dried using LGJ-18 Freeze Dryer (Thermo Scientific, Waltham, MA, USA), and stored at À20°C.
Separation and purification of RP-HPLC
Synthetic products were analyzed and purified by reversedphase high-performance liquid chromatography (RP-HPLC) on an Agilent Zorbax 300SB-C18 column (4.6 9 250 mm) with 5 lm silica as a stationary phase. A gradient elution with eluent A (water containing 0.1% TFA) and eluent B (acetonitrile containing 0.1% TFA) was used at a flow rate of 1.0 mLÁmin À1 . The detected wavelength is 220 or 254 nm. Gradient: 0-15-30 min corresponds to the range 20%-50%-20% of eluent B.
Analysis of mass spectra
The fractions of RP-HPLC main peak were collected and characterized by mass spectrometry. Mass spectra were performed on a Thermo-LCQ Advantage Mass Spectrometer (Thermo Fisher Scientific) fitted with an ion spray source working in positive ion mode and with methanol as the solvent.
CD spectra for the secondary structure of polypeptides After reacting 1 h at room temperature, their CD spectra were measured. The spectral range was 180-320 nm. The measurement scanning speed was 100 nmÁmin À1 , data was pitched every 1 nm, and three accumulations were taken for every spectrum. The path length was equal to 1 mm. The background absorption from all reagents was subtracted from the absorption spectra by using a corresponding solution with BRC analogas the reference solution.
Fluorescence emission spectroscopy measurements of p53 (171-192)-BRC analog
Steady-state fluorescence spectra were recorded in a quartz cell (light path 10 mm) on an F 23010 fluorescence spectrometer (Varian, Palo Alto, CA, USA). Different volumes of 1.0 9 10 À2 M p53 (171-192) solution were added to a series of 10 mL colorimetric tubes at fixed concentration of BRC (6.7 9 10 À3 M), respectively, and then was diluted to 10 mL in a colorimetric tube filled with Tris-HCl buffer solution (pH 7.4). After reacting 1 h at a room temperature, its fluorescence spectra was measured in the range of 280-400 nm at an excitation wavelength of 265 or 275 nm. The entrance and exit slits for all fluorescence measurements were both maintained at 10 nm.
Results and Discussion
Molecular structure simulation
The design idea of BRC analogous peptides is to construct a reasonable BRC2 molecular model and use ZDOCK and RDOCK for the molecular docking of BRC2 and p53 (171-192) to predict potentially key sites in BRC2 so as to obtain BRC analogs by mutation. We hope that mutation can alter the interaction of BRC analogs with p53 (171-192). First, the crystal structure of p53 was downloaded from the database (PDB bank: 2PCX), and the threedimensional structure of receptor p53 (171-192) was extracted using Discovery Studio 2017 R2 [16] . Then, the structure of BRC4 was taken from PDB entry 1N0W, and the molecular structure of BRC2 was constructed by 'Create Homology Models' in software using the polypeptide structure of BRC4 as a template.
Multiple possible structures of BRC2 can be obtained by homology modeling, though the sequence similarity of BRC2 and BRC4 is 71.4%. Based on the comparison of several scoring parameters, including DOPE score and PDF total energy, the best-scored structure was chosen as BRC2 structure [17, 18] . The quality of modeled structure was evaluated through Ramachandran plot. The evaluation of backbone Psi and Phi dihedral angles for BRC2 model revealed that 97.2% residues lie in favored regions, and only 2.8% residues (one Gly residue) lie in the outlier regions, indicating that the stereochemical revaluation for the model is reasonable (Fig. 1) .
The docking of BRC2 and p53 (171-192) was performed using ZDOCK program. The top 10 structures presenting the highest ZDOCK score were chosen and further optimized using the RDOCK [19] . The structure with the lowest E_RDOCK was shown in Fig. 2 , suggesting noncovalent interactions are the major driving forces in this peptide complex. So the alanine scanning mutagenesis approach was applied to calculate the peptide-peptide binding free energy (DDG bind ) [20] . In relation to DDG bind values, the mutation of Asn17Arg and Ala22Tyr in P4 caused the obvious change (DDG bind = À1.45 kcalÁmol
À1
) which may improve the stability of complex P4-p53 . Although the mutation energy (À0.15 kcalÁmol À1 ) in P5 is small, it indicated the cooperation among amino acid residues for three mutation sites in P5.
Design of mutant peptides
Eight highly conserved repeat motifs (BRC1-BRC8) in BRCA2 are all composed of 35 amino acid residues [5] . However, only BRC4 crystal structure data are available. The sequence is listed in Table 1 . BRC2 (1212-1246 sequence of BRCA2) and BRC4 present good sequence identity (34.3%). The BRC2 structure obtained by homology modeling presents comparatively low energy, indicating its stable structure and possible use for structural docking with the p53 (171-192) peptide [14] . The p53 (171-192) peptide is a conserved region of p53, which contains abundant active amino acid residues, such as Arg, His, and Glu. Mutations in this region likely are related to malignant transformation of tumors [21, 22] . During site-specific mutagenesis on BRC2, slight changes in BRC peptide structure may affect its interaction with p53 (171-192). Although the interaction between peptides is different from that of intact proteins, this interaction can also explain the fact that the mutation of BRC peptide may affect the interaction between BRCA2 and p53, which can provide useful information for the study of active peptides targeting p53.
Given the tendency of peptide chains to form secondary structures and the chemical nature of the amino acid residues, Phe at position 1216 in BRC2 of BRCA2, Thr at the 1225th position (conservative amino acid residues), and 1228Asn, 1233Ala, and 1235Gln (near the conservative amino acid residues) were selected to undergo mutation. Analogous peptide P1 was obtained by the mutation of 1235Gln to proline (Pro) for enhancing the solubility of the peptide on one hand and investigating whether Gln plays an important role in BRC2 on the other hand [23] . This function is attributed to 1235Gln being an amino acid residue that constitutes an a-helical structure and its location between the conservative amino acid residues 1234Leu and 1236Lys. Gln1235Pro mutation may affect the a-helix structure of BRC2, thereby affecting its interaction with p53. Based on P1, peptide P2 was obtained to replace the 1216 hydrophobic amino acid Phe with Pro to investigate whether the flexible structure of the N-terminus of BRC2 significantly affects the structure and function of the peptide [24] . Above the P2 mutation, the conservative amino acid residue Thr at position 1225 was mutated to Tyr, and P5 was obtained. Owing to the abundant conservative sites near the amide amino acid Asn at position 1228 in BRCA2 and the close spatial position of the a-helix structure of p53 (171-192), the mutation of Asn into Arg with high alkaline activity may affect the function of the peptide segment; thus, P3 was designed. Based on the design of P3, Ala1233Tyr mutation was added to obtain P4 to see whether P4 will further affect the interaction between peptides [25] .
Characterization of polypeptides
The ratio of different amino acids and condensation reagents was investigated during solid-phase synthesis of polypeptides. Finally, the condensation reaction was fast and efficient when the ratio between amino acids and condensation reagents was 1 : 3. After the synthesis was completed, a small amount of the product was dissolved in water, filtered through a membrane, and purified by RP-HPLC. The fraction was detected by ESI-MS, and the results are shown in Table 2 . The ESI-MS multiple charge peaks of the polypeptides were consistent with their theoretical molecular weights, indicating the successful synthesis of the target peptides.
Circular dichromatography for the interaction between p53 (171-192) and BRC Peptides
CD is a rapid and accurate method for studying the secondary structure of proteins. The intensity and position of circular dichroism bands produced by different secondary structures of polypeptides are different. The a-helix structure exhibits a positive peak at 192 nm and a negative peak at~208 nm, the bsheet presents a positive peak at 195 nm, the b-turn shows a weak negative peak at 220-230 nm, and the negative peak of~200 nm indicates an irregular Red letters indicate mutated amino acid residues. rolling structure. The change in the microstructure of the polypeptide can be reflected by changes in the CD spectra [26] . Therefore, the interaction between p53 (171-192) and the BRC polypeptide can be reflected by the change in displacement and intensity of the spectral band. Experimental data showed that the CD absorption intensity of p53 (171-192) changed significantly with the increase in concentration of BRC2 and its mutated peptide, and the addition of BRC peptide induced p53 (171-192) to show a positive peak at~200 nm. The negative peak at 204 nm gradually decreased, and red shift occurred beside P3 (Table 3 ). These findings show that the presence of BRC peptide affects the structure of p53 (171-192) and demonstrates a correlation between them. In particular, BRC2 analogs P1 and P4, which respectively reduced the proportion of the a-helical structure of p53 (171-192) from 55% to 20% and 35%, respectively, according to the neural network algorithm (K2D). This result shows that the mutation of amino acid residues in the a-helical structure of BRC2 exerts a marked influence on the interaction between BRC2-mutated peptide and p53 , especially the mutation between conservative amino acid residues Leu on 1234 and Lys on 1236. The CD spectrum of P5 was not determined for poor solubility.
With the increase in P3 concentration, the change in p53 (171-192) CD spectra was different from that of other polypeptides, the intensity of negative absorbance peak at 204 nm increased, and a blue shift occurred. The 200-210 nm range showed a significant negative peak, which is a characteristic absorption of the a-helical structure of the polypeptide, indicating that mutation in P3 did not lead to structural changes in p53 . This finding may be due to the mutation of Asn to alkaline Arg, thus changing the isoelectric point of the polypeptide to 8.44 (similar to that of BRC4), and the P3 with the positive charge under physiological conditions interacted with p53 (171-192) and resulted in electrostatic effects, which played a role in stabilizing the conformation of the polypeptide [27] . This interaction can explain how the crystal structure of BRC4 can be obtained. However, further mutation of P4 from 1233Ala on the basis of P3 led to a significant decrease in the proportion of p53 (171-192) a-helical structure to 35% and an increase in the ratio of b-sheet and bturn. This outcome also suggests that the change of ahelical structure of BRC2 considerably influences the interaction with p53 (171-192).
The change in CD spectra indicates that the change in BRC polypeptide structure affects the structure of , respectively (Fig. 3) ; these values all exceeded the maximum collision constant of diffusion regulation, 2 9 10 10 LÁmol À1 Ás
À1
. These findings indicated that the fluorescence quenching of the three polypeptides by p53 (171-192) involved static quenching [29] , with the two peptides forming a complex; however, the binding force of the mutant peptide with p53 (171-192) was reduced. On the basis of P1, the mutation of Phe on the N-terminal 1216 of BRC2 resulted in a small change, which shows that the change in a-helix in BRC2 considerably affects the structure and function of the peptide. This is also consistent with the interaction results of p53 (171-192) with P3, P4, and P5. Fluorescence spectroscopy can determine the interaction between polypeptide molecules but cannot accurately show the differences between polypeptide mutants, especially for mutants with small structural changes. Therefore, further research should be focused on the interaction between polypeptides and the spatial structure, which is our ongoing research topic.
Based on the crystal structure of BRC4 and p53 (171-192), the spatial structure of the interaction between BRC2 and p53 (171-192) can be simulated by homology modeling, providing structural basis for the site-specific mutation of BRC2. The results of CD and fluorescence spectroscopy show that the mutations of amino acid residues constituting the BRC2 a-helix significantly affect the structure and interaction of BRC and p53 . Although the exact structure of the polypeptide still needs further study, the experimental results in this work provide certain theoretical support for understanding the structure of the BRC repeat motif and its interaction pattern with p53.
